Anhco Nguyen
Chief Tech/Sci/R&D Officer en ATARA BIOTHERAPEUTICS, INC. .
Fortuna: 653 330 $ al 31/03/2024
Perfil
Anhco Nguyen's current job is as the Executive VP, Chief Scientific & Technical Officer at Atara Biotherapeutics, Inc. Dr. Nguyen's former jobs include being the Vice President-Research & Development at Enumeral Biomedical Holdings, Inc. from 2014 to 2016, an Associate at the Center for Cancer Research at Massachusetts Institute of Technology, and a Vice President at Fate Therapeutics, Inc. Dr. Nguyen's education includes a doctorate from the University of Washington and an undergraduate degree from Harvard College.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 04/03/2024 | 941 397 ( 0.73% ) | 653 330 $ | 31/03/2024 |
Cargos activos de Anhco Nguyen
| Empresas | Cargo | Inicio |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 10/05/2021 |
Antiguos cargos conocidos de Anhco Nguyen.
| Empresas | Cargo | Fin |
|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Chief Tech/Sci/R&D Officer | 17/08/2016 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formación de Anhco Nguyen.
| University of Washington | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
| Atara Biotherapeutics, Inc. |
- Bolsa de valores
- Insiders
- Anhco Nguyen
